open access

Vol 15, No 4 (2008)
Original articles
Published online: 2008-05-21
Submitted: 2013-01-14
Get Citation

The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value

Maciej Lewandowski, Zdzisława Kornacewicz-Jach, Barbara Millo, Joanna Zielonka, Małgorzata Czechowska, Robert Kaliszczak, Edyta Płońska, Jarosław Gorący, Jarosław Kaźmierczak, Marek Naruszewicz
Cardiol J 2008;15(4):357-364.

open access

Vol 15, No 4 (2008)
Original articles
Published online: 2008-05-21
Submitted: 2013-01-14

Abstract

Background: High-dose statins are used in acute coronary syndromes (ACS) to reduce inflammation. The aim of the study was the evaluation of the influence of low-dose atorvastatin (20 mg) on selected inflammatory parameters and clinical outcomes after ACS.
Methods: Seventy eight patients (pts) with ACS were randomly divided into group A (39 pts) taking atorvastatin, and group NA (39 pts) not taking any statin for the following six weeks. C-reactive protein (CRP), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor alpha (TNFa) levels were measured on the first and the fifth days and six weeks after ACS.
Results: There was no significant CRP and IL-6 level decrease in group A (CRP - 62%; IL-6 - 73%) or group NA (CRP - 44%; IL-6 - 62%). There was also no significant change in TNFa levels. The MCP-1 level finally reached the level of significant difference (p < 0.04). Cardiovascular events (MACE) and the restenosis rates did not differ between the groups.
Conclusions: Low-dose atorvastatin does not have a significant influence on cooling down inflammation in ACS, and MCP-1 can be used as an early indicator of statin anti-inflammatory activity. Furthermore, it does not reduce MACE or restenosis rates despite its influence on MCP-1 levels.

Abstract

Background: High-dose statins are used in acute coronary syndromes (ACS) to reduce inflammation. The aim of the study was the evaluation of the influence of low-dose atorvastatin (20 mg) on selected inflammatory parameters and clinical outcomes after ACS.
Methods: Seventy eight patients (pts) with ACS were randomly divided into group A (39 pts) taking atorvastatin, and group NA (39 pts) not taking any statin for the following six weeks. C-reactive protein (CRP), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor alpha (TNFa) levels were measured on the first and the fifth days and six weeks after ACS.
Results: There was no significant CRP and IL-6 level decrease in group A (CRP - 62%; IL-6 - 73%) or group NA (CRP - 44%; IL-6 - 62%). There was also no significant change in TNFa levels. The MCP-1 level finally reached the level of significant difference (p < 0.04). Cardiovascular events (MACE) and the restenosis rates did not differ between the groups.
Conclusions: Low-dose atorvastatin does not have a significant influence on cooling down inflammation in ACS, and MCP-1 can be used as an early indicator of statin anti-inflammatory activity. Furthermore, it does not reduce MACE or restenosis rates despite its influence on MCP-1 levels.
Get Citation

Keywords

atorvastatin; acute coronary syndrome; inflammation; CRP; IL-6; MCP-1; TNFa; restenosis

About this article
Title

The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value

Journal

Cardiology Journal

Issue

Vol 15, No 4 (2008)

Pages

357-364

Published online

2008-05-21

Bibliographic record

Cardiol J 2008;15(4):357-364.

Keywords

atorvastatin
acute coronary syndrome
inflammation
CRP
IL-6
MCP-1
TNFa
restenosis

Authors

Maciej Lewandowski
Zdzisława Kornacewicz-Jach
Barbara Millo
Joanna Zielonka
Małgorzata Czechowska
Robert Kaliszczak
Edyta Płońska
Jarosław Gorący
Jarosław Kaźmierczak
Marek Naruszewicz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl